Advertisement

Update on NCI in vitro drug screen utilities

  • S.L Holbeck
    Correspondence
    National Cancer Institute, Developmental Therapeutics Program, Information Technology Branch, 6130 Executive Blvd. Room 8014, Bethesda, MD 20892-7444, USA. Tel.: 301-435-9178; fax: 301-480-4808
    Affiliations
    National Cancer Institute, Developmental Therapeutics Program, Information Technology Branch, Rockville, MD, USA
    Search for articles by this author

      Abstract

      Development of new anti-cancer drugs is a costly and risky proposition. The Developmental Therapeutics Program (DTP) of the National Cancer Institutes of the United States (U.S.) facilitates the drug development process by providing access to preclinical screening services. Since the early 1990's, DTP has screened tens of thousands of compounds against a panel of 60 human tumour cell lines representing nine tissue sites. At the same time, DTP began to accumulate information on the expression of molecular entities in the same 60 cell line panel. Many of these data are freely available to the public at http://dtp.nci.nih.gov. More recently, additional, more focused screens have entered the picture, with data also available through the web site. These include screening of roughly 100 000 compounds against a panel of yeast mutants, and screening of the NCI Diversity Set in assays designed to detect effects on Molecular Targets of interest.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alvarez M
        • Paull K
        • Monks A
        • et al.
        Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
        J. Clin. Invest. 1995; 95 (PMID: 7738186): 2205-2214
        • Alvarez M
        • Robey R
        • Sandor V
        • et al.
        Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles.
        Mol. Pharmacol. 1998; 54: 802-814
        • Amundson S.A
        • Myers T.G
        • Scudiero D
        • Kitada S
        • Reed J.C
        • Fornace Jr., A.J
        An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
        Cancer Res. 2000; 60 (PMID: 11085534): 6101-6110
        • Blaskovich M.A
        • Sun J
        • Cantor A
        • Turkson J
        • Jove R
        • Sebti S.M
        Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
        Cancer Res. 2003; 62 (PMID: 12649187): 1270-1279
        • Bode C.J
        • Gupta M.L
        • Reiff E.A
        • Suprenant K.A
        • Georg G.I
        • Himes R.H
        Epothilone and paclitaxel.
        Biochemistry. 2002; 41: 3870-3874
        • Boyd M.R
        • Farina C
        • Belfiore P
        • et al.
        Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+) ATPases.
        J. Pharmacol. Exp. Ther. 2001; 297 (PMID: 11259534): 114-120
        • Budde R.J
        • Ke S
        • Levin V.A
        Activity of pp60c-src in 60 different cell lines derived from human tumors.
        Cancer Biochem Biophys. 1994; 14 (PMID: 7537173): 171-175
        • Bykov V.J
        • Issaeva N
        • Shilov A
        • et al.
        Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
        Nat. Med. 2002; 8 (PMID: 11875500): 282-288
        • Chandler L.A
        • Sosnowski B.A
        • Greenlees L
        • Aukerman S.L
        • Baird A
        • Pierce G.F
        Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines.
        Int. J. Cancer. 1999; 81 (PMID: 10209961): 451-458
        • Cleaveland E.S
        • Monks A
        • Vaigro-Wolff A
        • et al.
        Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.
        Biochem. Pharmacol. 1995; 49 (PMID: 7741767): 947-954
        • Duan Z
        • Feller A.J
        • Toh H.C
        • Makastorsis T
        • Seiden M.V
        TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line.
        Gene. 1999; 229 (PMID: 10095106): 75-81
        • Dunstan H.M
        • Ludlow C
        • Goehle S
        • et al.
        Cell-based assays for identification of novel double-strand break-inducing agents.
        J. Natl. Cancer Inst. 2002; 94 (PMID: 11792746): 88-94
        • Efferth T
        • Sauerbrey A
        • Halatsch M.E
        • Ross D.D
        • Gebhart E
        Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
        Naunyn Schmiedebergs Arch Pharmacol. 2003; 367 (PMID: 12616342): 56-67
        • Fitzsimmons S.A
        • Workman P
        • Grever M
        • Paull K
        • Camalier R
        • Lewis A.D
        Reductase enzyme expression across the National Cancer Institute Tumor cell line panel.
        J. Natl. Cancer Inst. 1996; 88: 259-269
        • Grem J.L
        • Danenberg K.D
        • Behan K
        • et al.
        Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
        Clin. Cancer Res. 2001; 7 (PMID: 11309351): 999-1009
      1. Holbeck SL, Simon J. The FHCRC/NCI yeast anticancer drug screen. In Nitiss JL, Heitman J, eds. Yeast as a Tool in Cancer Research, in press.

        • Imai Y
        • Nakane M
        • Kage K
        • et al.
        C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
        Mol. Cancer Ther. 2002; 1 (PMID: 12479221): 611-616
        • Izquierdo M.A
        • Shoemaker R.H
        • Flens M.J
        • et al.
        Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
        Int. J. Cancer. 1996; 65 (PMID: 8567122): 230-237
        • Kitada S
        • Krajewska M
        • Zhang X
        • et al.
        Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines.
        Am. J. Pathol. 1998; 152 (PMID: 9422523): 51-61
        • Koo H.M
        • Monks A
        • Mikheev A
        • et al.
        Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.
        Cancer Res. 1996; 56 (PMID: 8912859): 5211-5216
        • Krajewska M
        • Zapata J.M
        • Meinhold-Heerlein I
        • et al.
        Expression of Bcl-2 family member Bid in normal and malignant tissues.
        Neoplasia. 2002; 4 (PMID: 11896568): 129-140
        • Kubo A
        • Nakagawa K
        • Varma R.K
        • et al.
        The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
        Clin. Cancer Res. 1999; 5: 4279-4286
        • Lazo J.S
        • Aslan D.C
        • Southwick E.C
        • et al.
        Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
        J. Med. Chem. 2001; 44 (PMID: 11708908): 4042-4049
        • Lee J.S
        • Paull K
        • Alvarez M
        • et al.
        Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
        Mol. Pharmacol. 1994; 46: 627-638
        • Leteurtre F
        • Sackett D.L
        • Madalengoitia J
        • et al.
        Azatoxin derivatives with potent and selective action on topoisomerase II.
        Biochem. Pharmacol. 1995; 49 (PMID: 7763310): 1283-1290
        • Meinhold-Heerlein I
        • Stenner-Liewen F
        • Liewen H
        • et al.
        Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.
        Am. J. Pathol. 2001; 158 (PMID: 11290551): 1335-1344
        • Monks A
        • Scudiero D
        • Skehan P
        • et al.
        Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
        J. Natl. Cancer Inst. 1991; 83: 757-766
        • Moscow J.A
        • Connolly T
        • Myers T.G
        • Cheng C.C
        • Paull K
        • Cowan K.H
        Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines.
        Int. J. Cancer. 1997; 72 (PMID: 9212241): 184-190
        • Mu F
        • Coffing S.L
        • Riese 2nd D.J
        • et al.
        Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerisation.
        J. Med. Chem. 2001; 44 (PMID: 11462983): 441-452
        • Mulsch A
        • Schray-Utz B
        • Mordvintcev P.I
        • Hauschildt S
        • Busse R
        Diethyldithiocarbamate inhibits induction of macrophage NO synthase.
        FEBS Lett. 1993; 321: 215-218
        • Myers T.G
        • Anderson N.L
        • Waltham M
        • et al.
        A protein expression database for the molecular pharmacology of cancer.
        Electrophoresis. 1997; 18 (PMID: 9150955): 647-653
        • O'Connor P.M
        • Jackman J
        • Bae I
        • et al.
        Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
        Cancer Res. 1997; 57 (PMID: 9331090): 4285-4300
      2. Pasquale GD, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med in press. PMID: 14502277.

        • Paull K.D
        • Shoemaker R.H
        • Hodes L
        • et al.
        Display and analysis of patterns of differential activity of drugs against human tumor cell lines.
        J. Natl. Cancer Inst. 1989; 81: 1088-1092
        • Rapisarda A
        • Uranchimeg B
        • Scudiero D.A
        • et al.
        Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
        Cancer Res. 2002; 62 (PMID: 12154035): 4316-4324
        • Ross D.T
        • Scherf U
        • Eisen M.B
        • et al.
        Systematic variation in gene expression patterns in human cancer cell lines.
        Nat. Genet. 2000; 24: 227-235
        • Scheffer G.L
        • de Jong M.C
        • Monks A
        • et al.
        Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.
        Br. J. Cancer. 2002; 86 (PMID: 12085191): 1943-1950
        • Scherf U
        • Ross D.T
        • Waltham M
        • et al.
        A gene expression database for the molecular pharmacology of cancer.
        Nat. Genet. 2000; 24: 236-244
        • Schnier J.B
        • Nishi K
        • Monks A
        • Gorin F.A
        • Bradbury E.M
        Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression.
        Biochem. Biophys. Res. Commun. 2003; 309 (PMID: 12943673): 126-134
        • Solary E
        • Leteurtre F
        • Paull K.D
        • Scudiero D
        • Hamel E
        • Pommier Y
        Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
        Biochem. Pharmacol. 1993; 45 (PMID: 8392342): 2449-2456
        • Sreerama L
        • Sladek N.E
        Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents.
        Adv. Exp. Med. Biol. 1997; 414 (PMID: 9059610): 81-94
        • Stinson S.F
        • Alley M.C
        • Kopp W.C
        • et al.
        Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen.
        Anticancer Res. 1992; 12 (PMID: 1503399): 1035-1053
        • Takayama S
        • Krajewski S
        • Krajewska M
        • et al.
        Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines.
        Cancer Res. 1998; 58 (PMID: 9679980): 3116-3131
        • Tamm I
        • Kornblau S.M
        • Segall H
        • et al.
        Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
        Clin. Cancer Res. 2000; 6 (PMID: 10815900): 1796-1803
        • Tamm I
        • Wang Y
        • Sausville E
        • Scudiero D.A
        • Vigna N
        • Oltersdorf T
        • Reed J.C
        IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.
        Cancer Res. 1998; 58 (PMID: 9850056): 5315-5320
        • Taverna P
        • Liu L
        • Hanson A.J
        • Monks A
        • Gerson S.L
        Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
        Cancer Chemother. Pharmacol. 2000; 46 (PMID: 11138465): 507-516
        • Tew K.D
        • Monks A
        • Barone L
        • et al.
        Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program.
        Mol. Pharmacol. 1996; 50 (PMID: 8700107): 149-159
        • Vulevic B
        • Chen Z
        • Boyd J.T
        • et al.
        Cloning and characterization of human adenosine 5′-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2).
        Cancer Res. 2001; 61 (PMID: 11309290): 3339-3347
        • Washburn M.P
        • Koller A
        • Oshiro G
        • et al.
        Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae.
        Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 3107-3112
        • Weislow O.S
        • Kiser R
        • Fine D.L
        • Bader J
        • Shoemaker R.H
        • Boyd M.R
        New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity.
        J. Natl. Cancer Inst. 1989; 81: 577-586
        • Woo E.S
        • Monks A
        • Watkins S.C
        • Wang A.S
        • Lazo J.S
        Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel.
        Cancer Chemother. Pharmacol. 1997; 41 (PMID: 9443615): 61-68
        • Wosikowski K
        • Schuurhuis D
        • Johnson K
        • et al.
        Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
        J. Natl. Cancer Inst. 1997; 89: 1505-1515
        • Wu L
        • Smythe A.M
        • Stinson S.F
        • et al.
        Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
        Cancer Res. 1992; 52 (PMID: 1350507): 3029-3034
        • Xia Y
        • Yang Z.Y
        • Xia P
        • et al.
        Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents.
        J. Med. Chem. 2001; 44 (PMID: 11689079): 3932-3936
        • Xu Z
        • Chen Z.P
        • Malapetsa A
        • et al.
        DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.
        Anticancer Drugs. 2002; 13 (PMID: 12045463): 511-519
        • Yu L.J
        • Matias J
        • Scudiero D.A
        • et al.
        P450 enzyme expression patterns in the NCI human tumor cell line panel.
        Drug Metab. Dispos. 2001; 29 (PMID: 11181500): 304-312
        • Zaharevitz D.W
        • Gussio R
        • Leost M
        • et al.
        Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
        Cancer Res. 1999; 59: 2566-2569